DK1490355T3 - Indolylmaleimidderivater - Google Patents

Indolylmaleimidderivater

Info

Publication number: DK1490355T3
Authority: DK; Denmark
Prior art keywords: indolylmaleimide derivatives; indolylmaleimide; derivatives
Prior art date: 2002-04-03

Application number

DK03720413.8T

Other languages

English (en)

Inventor

Jean-Pierre Evenou

Matt Peter Von

Juergen Wagner

Gerhard Zenke

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-03

Filing date

2003-04-02

Publication date

2011-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1490355(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-03 Priority claimed from GB0207729A external-priority patent/GB0207729D0/en

2003-02-13 Priority claimed from GB0303323A external-priority patent/GB0303323D0/en

2003-04-02 Application filed by Novartis Ag filed Critical Novartis Ag

2011-11-21 Application granted granted Critical

2011-11-21 Publication of DK1490355T3 publication Critical patent/DK1490355T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)

DK03720413.8T 2002-04-03 2003-04-02 Indolylmaleimidderivater DK1490355T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207729A GB0207729D0 (en)	2002-04-03	2002-04-03	Organic compounds
GB0303323A GB0303323D0 (en)	2003-02-13	2003-02-13	Organic compounds
PCT/EP2003/003470 WO2003082859A1 (en)	2002-04-03	2003-04-02	Indolylmaleimide derivatives

Publications (1)

Publication Number	Publication Date
DK1490355T3 true DK1490355T3 (da)	2011-11-21

Family

ID=28676503

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03720413.8T DK1490355T3 (da)	2002-04-03	2003-04-02	Indolylmaleimidderivater

Country Status (26)

Country	Link
US (5)	US20050119274A1 (da)
EP (1)	EP1490355B1 (da)
JP (1)	JP4247125B2 (da)
KR (2)	KR100942329B1 (da)
CN (1)	CN100351251C (da)
AR (1)	AR039209A1 (da)
AT (1)	ATE517888T1 (da)
AU (1)	AU2003224031B2 (da)
BR (1)	BR0308979A (da)
CA (1)	CA2477774C (da)
CO (1)	CO5611127A2 (da)
CY (1)	CY1111982T1 (da)
DK (1)	DK1490355T3 (da)
EC (2)	ECSP045254A (da)
IL (1)	IL163892A0 (da)
MX (1)	MXPA04009632A (da)
MY (1)	MY137566A (da)
NO (1)	NO329166B1 (da)
NZ (1)	NZ535613A (da)
PE (1)	PE20040079A1 (da)
PL (1)	PL213480B1 (da)
PT (1)	PT1490355E (da)
RU (1)	RU2340610C2 (da)
SI (1)	SI1490355T1 (da)
TW (2)	TW200918046A (da)
WO (1)	WO2003082859A1 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6645970B2 (en) *	2000-11-07	2003-11-11	Novartis Ag	Indolylmaleimide derivatives
PE20040079A1 (es) *	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
GB0303319D0 (en) *	2003-02-13	2003-03-19	Novartis Ag	Organic compounds
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
ZA200602051B (en)	2003-08-13	2007-10-31	Takeda Pharmaceutical	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP2007509185A (ja) *	2003-10-27	2007-04-12	ノバルティスアクチエンゲゼルシャフト	βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
US7582631B2 (en)	2004-01-14	2009-09-01	Amgen Inc.	Substituted heterocyclic compounds and methods of use
JP2007518730A (ja) *	2004-01-19	2007-07-12	ノバルティスアクチエンゲゼルシャフト	インドリルマレイミド誘導体
EP1734952A1 (en) *	2004-04-08	2006-12-27	Novartis AG	Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
GB0410713D0 (en)	2004-05-13	2004-06-16	Novartis Ag	Organic compounds
GB0504203D0 (en) *	2005-03-01	2005-04-06	Novartis Ag	Organic compounds
JP4747364B2 (ja) *	2005-04-04	2011-08-17	独立行政法人産業技術総合研究所	紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
GB0507918D0 (en)	2005-04-19	2005-05-25	Novartis Ag	Organic compounds
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
GB0511060D0 (en)	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
ATE496044T1 (de) *	2005-07-11	2011-02-15	Novartis Ag	Indolylmaleimidderivate
EP1749523A1 (en) *	2005-07-29	2007-02-07	Neuropharma, S.A.	GSK-3 inhibitors
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
PE20070522A1 (es)	2005-09-14	2007-07-11	Takeda Pharmaceutical	2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
DK2848258T3 (da)	2005-10-26	2018-03-19	Novartis Ag	Behandling af familiær middelhavsfeber med anti-IL-1beta-antistoffer
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US9006224B2 (en)	2005-11-21	2015-04-14	Novartis Ag	Neuroendocrine tumor treatment
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
GB0605691D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
GB0613162D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic compounds
JP2010501586A (ja) *	2006-08-23	2010-01-21	ノバルティスアクチエンゲゼルシャフト	眼疾患におけるｐｋｃ阻害剤、特にインドリルマレイミド誘導体の使用
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
MX2009005945A (es) *	2006-12-07	2009-06-17	Novartis Ag	Uso de inhibidores de pkc en transplantes.
CN101558062A (zh)	2006-12-19	2009-10-14	诺瓦提斯公司	作为激酶抑制剂的吲哚基马来酰亚胺衍生物
CN101754682B (zh) *	2007-05-16	2014-11-12	布里格姆妇女医院	突触核蛋白病的治疗
AU2008257520B2 (en)	2007-05-29	2012-04-05	Novartis Ag	New indications for anti- IL-I-beta therapy
US20090054513A1 (en) *	2007-08-22	2009-02-26	Response Scientific, Inc.	Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en)	2007-08-22	2011-05-17	Response Scientific, Inc.	Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
JP2011515068A (ja)	2007-11-08	2011-05-19	ノバルティスアーゲー	慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー
AR069799A1 (es) *	2007-12-21	2010-02-17	Novartis Ag	Composicion farmaceutica
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
ES2331451B1 (es) *	2008-06-30	2010-10-21	Consejo Superior De Investigaciones Cientificas (Csic)	Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
WO2010042433A1 (en)	2008-10-06	2010-04-15	Bristol-Myers Squibb Company	Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
DE202008014557U1 (de)	2008-10-27	2009-03-12	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Therapeutische Verwendung
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN101671329B (zh) *	2009-06-17	2012-11-07	东华大学	3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用
CA2767616A1 (en)	2009-07-09	2011-01-13	The Scripps Research Institute	Gene expression profiles associated with chronic allograft nephropathy
TWI535440B (zh) *	2009-10-26	2016-06-01	Ｌｇ生命科學有限公司	包括吲哚化合物之醫藥組成物
US8791100B2 (en)	2010-02-02	2014-07-29	Novartis Ag	Aryl benzylamine compounds
CA2795456A1 (en)	2010-03-30	2011-10-06	Novartis Ag	Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
US8785648B1 (en)	2010-08-10	2014-07-22	The Regents Of The University Of California	PKC-epsilon inhibitors
EA031849B1 (ru)	2010-08-23	2019-03-29	Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем	Антитела к ox40 и способы их применения
CZ305457B6 (cs) *	2011-02-28	2015-09-30	Ústav organické chemie a biochemie, Akademie věd ČR v. v. i.	Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
UY34072A (es)	2011-05-17	2013-01-03	Novartis Ag	Derivados sustituidos de indol
MX2013015001A (es)	2011-06-27	2014-03-31	Novartis Ag	Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
US9233111B2 (en)	2011-07-08	2016-01-12	Novartis Ag	Pyrrolo pyrimidine derivatives
JP2014530851A (ja)	2011-10-21	2014-11-20	ノバルティスアーゲー	Ｐｉ３ｋモジュレータとしてのキナゾリン誘導体
AP2014007680A0 (en)	2011-12-02	2014-06-30	Novartis Ag	Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
MX351530B (es)	2011-12-15	2017-10-18	Novartis Ag	Uso de inhibidores de la actividad o fundicion de la pi3k.
IN2014CN04174A (da)	2011-12-22	2015-09-04	Novartis Ag
EP2794594A1 (en)	2011-12-22	2014-10-29	Novartis AG	Quinoline derivatives
US20150284364A1 (en)	2012-11-07	2015-10-08	Nicole Bieri	Substituted indole derivatives
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
DK2925366T3 (da)	2012-11-29	2018-06-06	Novartis Ag	Farmaceutiske kombinationer
EP2948134B1 (en)	2013-01-24	2020-03-04	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mtor inhibitors
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JP6494633B2 (ja)	2013-09-22	2019-04-03	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されているアミノピリミジン化合物および使用方法
KR101630806B1 (ko)	2013-11-14	2016-06-16	대한민국	돼지의 초위성체 마커를 이용한 개체식별 방법
US9512084B2 (en)	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
EP3122728A4 (en)	2014-03-28	2017-10-25	Calitor Sciences, LLC	Substituted heteroaryl compounds and methods of use
CA2945212A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
PT3134396T (pt)	2014-04-24	2019-12-16	Novartis Ag	Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
CN106458966B (zh)	2014-04-24	2019-05-07	诺华股份有限公司	作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
US10443100B2 (en)	2014-05-22	2019-10-15	The Scripps Research Institute	Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3146077A4 (en)	2014-05-22	2018-05-02	The Scripps Research Institute	Tissue molecular signatures of kidney transplant rejections
US11104951B2 (en)	2014-05-22	2021-08-31	The Scripps Research Institute	Molecular signatures for distinguishing liver transplant rejections or injuries
EP3180003B1 (en)	2014-07-01	2022-01-12	The Regents of the University of California	Pkc-epsilon inhibitors
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
CN115109158A (zh)	2015-05-07	2022-09-27	阿吉纳斯公司	抗ox40抗体及其使用方法
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
CA3007233A1 (en)	2015-12-02	2017-06-08	Agenus Inc.	Antibodies and methods of use thereof
EP3538152A4 (en)	2016-11-09	2020-09-30	Agenus Inc.	ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
US10722499B2 (en)	2017-01-06	2020-07-28	Palvella Therapeutics, Inc.	Anyhydrous compositions of mTOR inhibitors and methods of use
WO2018175302A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Reduced exposure conjugates modulating therapeutic targets
JP7254076B2 (ja)	2017-11-19	2023-04-07	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	置換ヘテロアリール化合物及び使用方法
EP3740468A4 (en)	2018-01-20	2021-10-06	Sunshine Lake Pharma Co., Ltd.	SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
CN110551103B (zh)	2018-05-30	2022-08-23	北京大学深圳研究生院	一种jak3选择性抑制剂
WO2020010073A1 (en)	2018-07-02	2020-01-09	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
MX2021014157A (es)	2019-05-23	2022-01-04	Novartis Ag	Formas cristalinas de un inhibidor btk.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
KR20010085305A (ko) *	1998-07-30	2001-09-07	미즈노 마사루	이치환된 말레이미드 화합물 및 그의 의약 용도
US6281356B1 (en) *	1999-12-22	2001-08-28	Hoffmann-La Roche Inc.	Substituted pyrroles
IL153851A0 (en) *	2000-07-27	2003-07-31	Hoffmann La Roche	3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
US6645970B2 (en) *	2000-11-07	2003-11-11	Novartis Ag	Indolylmaleimide derivatives
ATE445613T1 (de) *	2000-11-07	2009-10-15	Novartis Pharma Gmbh	Indolylmaleimidderivative als proteinkinase-c- inhibitoren
PE20040079A1 (es) *	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
JP2007509185A (ja) *	2003-10-27	2007-04-12	ノバルティスアクチエンゲゼルシャフト	βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体

2003
- 2003-04-01 PE PE2003000330A patent/PE20040079A1/es not_active Application Discontinuation
- 2003-04-01 AR ARP030101128A patent/AR039209A1/es active IP Right Grant
- 2003-04-01 TW TW097141220A patent/TW200918046A/zh unknown
- 2003-04-01 TW TW092107388A patent/TWI324064B/zh not_active IP Right Cessation
- 2003-04-02 CN CNB038053438A patent/CN100351251C/zh not_active Expired - Lifetime
- 2003-04-02 DK DK03720413.8T patent/DK1490355T3/da active
- 2003-04-02 EP EP03720413A patent/EP1490355B1/en not_active Expired - Lifetime
- 2003-04-02 BR BR0308979-7A patent/BR0308979A/pt not_active IP Right Cessation
- 2003-04-02 US US10/510,027 patent/US20050119274A1/en not_active Abandoned
- 2003-04-02 IL IL16389203A patent/IL163892A0/xx unknown
- 2003-04-02 RU RU2004132203/04A patent/RU2340610C2/ru not_active IP Right Cessation
- 2003-04-02 MX MXPA04009632A patent/MXPA04009632A/es active IP Right Grant
- 2003-04-02 KR KR1020077007917A patent/KR100942329B1/ko not_active IP Right Cessation
- 2003-04-02 PT PT03720413T patent/PT1490355E/pt unknown
- 2003-04-02 NZ NZ535613A patent/NZ535613A/en not_active IP Right Cessation
- 2003-04-02 CA CA2477774A patent/CA2477774C/en not_active Expired - Lifetime
- 2003-04-02 JP JP2003580325A patent/JP4247125B2/ja not_active Expired - Lifetime
- 2003-04-02 WO PCT/EP2003/003470 patent/WO2003082859A1/en active Application Filing
- 2003-04-02 SI SI200332053T patent/SI1490355T1/sl unknown
- 2003-04-02 AT AT03720413T patent/ATE517888T1/de active
- 2003-04-02 AU AU2003224031A patent/AU2003224031B2/en not_active Expired
- 2003-04-02 MY MYPI20031225A patent/MY137566A/en unknown
- 2003-04-02 KR KR1020047015591A patent/KR100886521B1/ko not_active IP Right Cessation
- 2003-04-02 PL PL371322A patent/PL213480B1/pl unknown
2004
- 2004-08-27 EC EC2004005254A patent/ECSP045254A/es unknown
- 2004-09-15 CO CO04091784A patent/CO5611127A2/es active IP Right Grant
- 2004-10-26 NO NO20044613A patent/NO329166B1/no not_active IP Right Cessation
2006
- 2006-10-12 US US11/546,693 patent/US7235555B2/en not_active Expired - Lifetime
- 2006-10-12 US US11/546,690 patent/US7358253B2/en not_active Expired - Lifetime
2007
- 2007-10-25 US US11/977,565 patent/US20080108628A1/en not_active Abandoned
2008
- 2008-02-21 US US12/034,675 patent/US7534808B2/en not_active Expired - Lifetime
- 2008-12-12 EC EC2008005254A patent/ECSP085254A/es unknown
2011
- 2011-10-27 CY CY20111101021T patent/CY1111982T1/el unknown

Also Published As

Publication number	Publication date
CA2477774C (en)	2011-03-15
NO329166B1 (no)	2010-09-06
WO2003082859A1 (en)	2003-10-09
EP1490355B1 (en)	2011-07-27
US20070032507A1 (en)	2007-02-08
AR039209A1 (es)	2005-02-09
SI1490355T1 (sl)	2011-11-30
JP4247125B2 (ja)	2009-04-02
US20050119274A1 (en)	2005-06-02
US7358253B2 (en)	2008-04-15
AU2003224031A1 (en)	2003-10-13
CO5611127A2 (es)	2006-02-28
RU2340610C2 (ru)	2008-12-10
TWI324064B (en)	2010-05-01
KR20070043900A (ko)	2007-04-25
KR100886521B1 (ko)	2009-03-02
MY137566A (en)	2009-02-27
US20070037826A1 (en)	2007-02-15
US7235555B2 (en)	2007-06-26
TW200918046A (en)	2009-05-01
KR20040094901A (ko)	2004-11-10
PL213480B1 (pl)	2013-03-29
AU2003224031B2 (en)	2007-06-28
KR100942329B1 (ko)	2010-02-12
US20080108628A1 (en)	2008-05-08
JP2005527563A (ja)	2005-09-15
CN1639153A (zh)	2005-07-13
US20080146578A1 (en)	2008-06-19
PE20040079A1 (es)	2004-04-19
ECSP045254A (es)	2004-09-28
ECSP085254A (es)	2009-01-30
MXPA04009632A (es)	2005-01-11
PL371322A1 (en)	2005-06-13
US7534808B2 (en)	2009-05-19
NZ535613A (en)	2007-07-27
NO20044613L (no)	2004-10-26
RU2004132203A (ru)	2005-07-10
ATE517888T1 (de)	2011-08-15
CN100351251C (zh)	2007-11-28
IL163892A0 (en)	2005-12-18
CY1111982T1 (el)	2015-11-04
EP1490355A1 (en)	2004-12-29
TW200306818A (en)	2003-12-01
BR0308979A (pt)	2005-01-04
PT1490355E (pt)	2011-11-03
CA2477774A1 (en)	2003-10-09

Publication	Publication Date	Title
ATE517888T1 (de)	2011-08-15	Indolylmaleimid-derivate
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
ATE340782T1 (de)	2006-10-15	Piperidinbenzolsulfonamidderivate
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
DE60336314D1 (de)	2011-04-21	Substituierte indole
IS7667A (is)	2005-01-27	Nýjar bensimídazólafleiður
ATE420066T1 (de)	2009-01-15	Amidoacetonitrilderivate
ATE352550T1 (de)	2007-02-15	Chinazolinderivate
DK1606277T3 (da)	2008-08-18	Imidazol-4-yl-ethynyl-pyridinderivater
IS8364A (is)	2006-03-20	N-þíasól-2-ýl-bensamíð afleiður
ATE386518T1 (de)	2008-03-15	Benzimidazolderivate
ATE335729T1 (de)	2006-09-15	3h-chinazoline -4-on derivaten
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
DK1706373T3 (da)	2010-01-18	Amidoacetonitrilderivater
ATE457299T1 (de)	2010-02-15	4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
IS7833A (is)	2005-05-02	Efnasambönd með sameinaða heteróhringi
IS8045A (is)	2005-09-26	Púrín-6-ón-afleiður
ATE427945T1 (de)	2009-04-15	Imidazolderivate
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate